Compugen Ltd (CGEN) stock
CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.10−0.02 (-0.94%)
Close on Nov 13, 2026Market cap $198.56MP/E 5.5Yield –
Compugen EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was $0.38. The highest annual figure on record is $0.38 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0.38 | – |
| FY2024 | Dec 31, 2024 | -$0.16 | – |
| FY2023 | Dec 31, 2023 | -$0.21 | – |
| FY2022 | Dec 31, 2022 | -$0.39 | – |
| FY2021 | Dec 31, 2021 | -$0.41 | – |
| FY2020 | Dec 31, 2020 | -$0.37 | – |
| FY2019 | Dec 31, 2019 | -$0.43 | – |
| FY2018 | Dec 31, 2018 | -$0.41 | – |
| FY2017 | Dec 31, 2017 | -$0.72 | – |
| FY2016 | Dec 31, 2016 | -$0.62 | – |
| FY2015 | Dec 31, 2015 | -$0.40 | – |
| FY2014 | Dec 31, 2014 | -$0.26 | – |
| FY2013 | Dec 31, 2013 | -$0.36 | – |
| FY2012 | Dec 31, 2012 | -$0.38 | – |
| FY2011 | Dec 31, 2011 | -$0.35 | – |
| FY2010 | Dec 31, 2010 | -$0.22 | – |
| FY2009 | Dec 31, 2009 | -$0.13 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?